POLE and neoplasm: Although assessment of mismatch repair deficiency (MMRd) and p53 abnormalities by IHC is increasingly performed, assessment of POLE status is required for correct molecular classification and allocation of adjuvant therapy.17 Finally, a cheap, accessible, and rapid assay, which enables assessment of POLE status on tumor material obtained by biopsy or hysterectomy, will aid in counseling and decisions on lymphadenectomy and (neo)adjuvant therapy.